On August 11, ASYMCHEM rose 5.07% in regular trading, trading at HKD 130.0/share, with turnover of HKD 73.22 million. The stock continues its catch-up rally following its A-share hitting the daily limit on August 7.
On the news front, CXO sector leader WuXi AppTec previously reported robust interim results, with first-half revenue of RMB 28.897 billion representing a 38.93% year-over-year increase, while non-recurring adjusted net profit surged 89.39% YoY. WuXi AppTec also raised its full-year guidance, sending a strong signal of sector recovery that has broadly lifted medical outsourcing stocks. Separately, ASYMCHEM recently announced a RMB 1.24 billion capital injection into its subsidiary ASYMCHEM BIO, jointly with Hillhouse Capital affiliate and Chairman Dr. Hao Hong, to expand macromolecule CDMO capacity. The company also plans to adopt a restricted H-share incentive plan, with an extraordinary general meeting scheduled for August 20.
Research institutions have noted that the CXO industry has entered a new upcycle driven by global biotech financing recovery, rising domestic business development activity, and accelerating demand across novel modalities, reinforcing growth visibility for the sector.
(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)
Comments